Basse Wavre, Walloon Region, Belgium
Consultance and advices in chemistry and pharmaceutical formulations, microencapsulations, slow release delivery systems...
Developing new vaccine formulations, new adjuvant and devices. Interactions with outside research institutions and internal QC, QA, scaling up and manufacturing. Winner of the “2012 Best Innovator Award” (GSK internal competition from different countries to favour new concepts and ideas in the vaccine field). Dec 2012- Dec 2014: Capitain of the CalFO i4venture: New calcium fluoride composite nanoparticles for antigen adsorption, stability and adjuvant effect: Inventor of GSK patents WO2015059224A1, WO2015059225A1. inventor of GSK Patents PCT/EP2006/001442 Live attenuated Rotavirus vaccine for oral administration; and WO 02/13858 A1 : Development of « Lyoc » type of formula for oral delivery of antigens. Co inventor of GSK Patent WO 01/ 12797; Rotavirus oral delivery formula: Development of the lyophilisation formula and creation of the CaCO3 antacid part. Co inventor of GSK Patent WO02/30458 A1: Development of formula for oral delivery particles comprising a Yersinia adhesion protein.
Research, faisibility and services in the domain of microencapsulation. Development of microencapsulation using supercritical CO2 technics: Centre de Microencapsulation patent, WO 96/11055: Method of coating particles.
Involved in the synthesis of biodegradable polymers, and their uses in new drug deliver systems. Synthesis of polylactic acid. Manufacturing and scaling up production according to GMP and GMP of PLAG microspheres, loaded with several biologically active peptides, for intramuscular injections. In charge of scaling up the synthesis of actives pharmaceutical products for use in clinical trials inside and outside our institution, according to GMP. Writing and submitting Drug Master Files to the US Food and Drug Administration.
Program supported by S.A. SOPAR, involving the organic synthesis of glyceridic produrgs of L-DOPA having anti-Parkinson activities.